Aspira Womens Health Inc (AWH)

Add to Watchlists
Create an Alert
Quickflows
6.23 -0.07  -1.11% NASDAQ Apr 9, 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All AWH News

News

View All Events

Events

Date Type Description
05/14/2020 16:30 EDT Earnings Calls Q1 2020 Earnings Call
05/14/2020 00:00 Earnings Results Q1 2020 Earnings Results
06/23/2020 08:00 EDT Agm 2019 Annual General Meeting
08/13/2020 16:30 EDT Earnings Calls Q2 2020 Earnings Call
08/13/2020 00:00 Earnings Results Q2 2020 Earnings Results
11/12/2020 16:30 EST Earnings Calls Q3 2020 Earnings Call
11/12/2020 00:00 Earnings Results Q3 2020 Earnings Results
03/25/2021 00:00 Earnings Results Q4 2020 Earnings Results
03/25/2021 16:30 EDT Earnings Calls Q4 2020 Earnings Call
05/14/2021 00:00 Earnings Results Q1 2021 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 4.651M
Total Expenses (TTM) 22.63M
Net Income (TTM) -17.90M

Balance Sheet View Statement

Total Assets (Quarterly) 19.60M
Total Liabilities (Quarterly) 9.886M
Shareholders Equity (Quarterly) 9.719M

Cash Flow Statement View Statement

Cash from Operations (TTM) -14.73M
Cash from Investing (TTM) -0.49M
Cash from Financing (TTM) 20.15M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.aspirawh.com
  • Investor Relations URL: http://phx.corporate-ir.net/phoenix.zhtml?c=121814&p=irol-IRHome
  • HQ State/Province: Texas
  • Sector: Healthcare
  • Industry: Diagnostics & Research
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: May. 14, 2021
  • Last Earnings Release: Mar. 25, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Aspira Womens Health Inc is transforming women's health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 plus combines its FDA-cleared products OVA1 and OVERA to detect the risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiX testing offers both targeted and a more comprehensive genetic testing options with a gynecologic focus. Its focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 6.23
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
SCGNX Friess Small Cap Growth Investor 2.55%

Comparables

Edit
BRKR Bruker Corp
HBIO Harvard Bioscience Inc
PACB Pacific Biosciences of California Inc
FLDM Fluidigm Corp
AXDX Accelerate Diagnostics Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.